Epirubicin hydrochloride injection 10 mg in 5 mL (7)

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

epirubicin hydrochloride, Quantity: 2 mg/mL

Pieejams no:

Pfizer (Perth) Pty Ltd

Zāļu forma:

Injection, solution

Kompozīcija:

Excipient Ingredients: sodium chloride; hydrochloric acid; water for injections

Ievadīšanas:

Intravenous Infusion, Intravesical

Vienības iepakojumā:

1 X 5 mL

Receptes veids:

(S1) This Schedule is intentionally blank

Ārstēšanas norādes:

FARMORUBICIN PFS is recommended for use in the treatment of the following types of cancer: - Transitional cell bladder cancer - Early-stage, advanced and/or metastatic breast cancer - Gastric cancer - Palliative chemotherapy for cancer of the oesophago-gastric junction - Head and neck cancers - Leukaemia - Non-small cell lung cancer (NSCLC) - Small cell lung cancer (SCLC) - Non-Hodgkin lymphomas (NHLs), Hodgkin lymphoma (HL) - Multiple myeloma - Ovarian cancer - Pancreatic cancer treated with the combined cisplatin, epirubicin, 5-fluorouracil and gemcitabine (PEFG) regimen - Bowel cancer - Soft tissue sarcomas.

Produktu pārskats:

Visual Identification: Clear and clean red solution; Container Type: Vial; Container Material: PP; Container Life Time: 36 Months; Container Temperature: Store at 2 to 8 degrees Celsius; Container Closure: Neither child resistant closure nor restricted flow insert

Autorizācija statuss:

Listed (Export Only)

Autorizācija datums:

2018-11-20